IDH2 and glioblastoma: These tumors also occur at a younger age than their IDH-wildtype GBM counterparts (5th decade compared to 7th decade, respectively) [34,52,105,106], and have increased rates of TP53 and ATRX mutation as well as lower rates of TERTp mutation, PTEN mutation, and EGFR amplification [107].